Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B C Vrouenraets

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 21, 1999
Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalanB C Vrouenraets, G J in't Veld, O E Nieweg, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 18, 2006
Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusionE M Noorda, B C Vrouenraets, O E Nieweg, et al.
Journal of Gastrointestinal Cancer|December 18, 2008
Outcome of rectal cancer surgery after the introduction of preoperative radiotherapy in a low-volume hospitalA Doeksen, P J Tanis, B C Vrouenraets, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 20, 2003
Prognostic factors for survival after isolated limb perfusion for malignant melanomaE M Noorda, B C Vrouenraets, O E Nieweg, et al.
Journal of the American College of Surgeons|June 1, 1996
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbsW M Klop, B C Vrouenraets, B N van Geel, et al.
Annals of Surgical Oncology|June 24, 1999
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalanB C Vrouenraets, B B Kroon, A C Ogilvie, et al.
Journal of the American College of Surgeons|May 11, 1999
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanomaB C Vrouenraets, G A Hart, A M Eggermont, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2001
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan aloneB C Vrouenraets, A M Eggermont, A A Hart, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1993
Regional isolated perfusion with melphalan for patients with subungual melanomaB C Vrouenraets, B B Kroon, J M Klaase, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 16, 2007
The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusionE M Noorda, R H J van Kreij, B C Vrouenraets, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|October 21, 1999
Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalanB C Vrouenraets, G J in't Veld, O E Nieweg, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 18, 2006
Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusionE M Noorda, B C Vrouenraets, O E Nieweg, et al.
Journal of Gastrointestinal Cancer|December 18, 2008
Outcome of rectal cancer surgery after the introduction of preoperative radiotherapy in a low-volume hospitalA Doeksen, P J Tanis, B C Vrouenraets, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 20, 2003
Prognostic factors for survival after isolated limb perfusion for malignant melanomaE M Noorda, B C Vrouenraets, O E Nieweg, et al.
Journal of the American College of Surgeons|June 1, 1996
Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbsW M Klop, B C Vrouenraets, B N van Geel, et al.
Annals of Surgical Oncology|June 24, 1999
Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-alpha and melphalanB C Vrouenraets, B B Kroon, A C Ogilvie, et al.
Journal of the American College of Surgeons|May 11, 1999
Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanomaB C Vrouenraets, G A Hart, A M Eggermont, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 22, 2001
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan aloneB C Vrouenraets, A M Eggermont, A A Hart, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1993
Regional isolated perfusion with melphalan for patients with subungual melanomaB C Vrouenraets, B B Kroon, J M Klaase, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 16, 2007
The health-related quality of life of long-term survivors of melanoma treated with isolated limb perfusionE M Noorda, R H J van Kreij, B C Vrouenraets, et al.
Pageof 6